Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation (NASDAQ: NEOG) generates a steady flow of news related to food safety, animal safety, and global food security. As a Lansing, Michigan-based manufacturer of diagnostics and related products, Neogen regularly issues updates on its financial performance, segment trends, and strategic actions that affect the Food Safety and Animal Safety markets.
On this page, readers can follow earnings releases where Neogen reports revenue, segment performance, gross margin, and non-GAAP measures such as adjusted EBITDA. These updates often break out results for the Food Safety and Animal Safety segments, discuss core revenue trends versus divestitures and discontinued product lines, and provide commentary on product categories like pathogen detection, indicator testing, culture media, biosecurity, and genomics.
Neogen’s news flow also includes announcements about leadership changes, such as the appointment of a new President and Chief Executive Officer, Chief Financial Officer, and senior commercial and business unit leaders. Board transitions, including director retirements and new director appointments, are disclosed through both press releases and related SEC filings.
Sector-specific items appear in Neogen’s news as well, including collaborations in equine health and vaccine offerings such as BotVax B for botulism Type B in horses. The company also announces participation in investor conferences and the timing of quarterly earnings calls and webcasts.
By reviewing the NEOG news feed on this page, investors and observers can track how Neogen describes its progress in food safety, livestock, and pet health and wellness, as well as its strategic transformation efforts, restructuring actions, and capital allocation decisions over time.
Neogen (NASDAQ: NEOG) appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025. Riggsbee will lead Neogen’s global finance organization and join the Executive Leadership Team, reporting to CEO Mike Nassif. To support a smooth changeover, David Naemura is expected to remain through the end of the calendar year.
Riggsbee brings over 25 years of financial leadership in diagnostics and healthcare, most recently serving as CFO of bioMérieux’s $2 billion North American business and previously as CFO at Myriad Genetics; prior roles include LabCorp, GE, and KPMG. He holds degrees from UNC Chapel Hill, North Carolina State, and an MBA from Kellogg.
Neogen (NASDAQ: NEOG) reported fiscal Q1 2026 results for the quarter ended August 31, 2025: revenue $209.2M, net income $36.3M (EPS $0.17), Adjusted Net Income $9.4M, and Adjusted EBITDA $35.5M (17.0% margin). Gross margin was 45.4% (49.5% ex-integration costs). The company completed the divestiture of its Cleaners & Disinfectants business and used proceeds to repay $100.0M of debt, leaving total debt at $800.0M and cash of $138.9M. Mike Nassif became CEO and President effective August 11, 2025. Company implemented restructuring and headcount reductions and reaffirmed full-year FY2026 guidance of $820M–$840M revenue and $165M–$175M Adjusted EBITDA.
Neogen Corporation (NASDAQ: NEOG) has renewed its sponsorship with the United States Equestrian Federation, extending their partnership that began in April 2024. The collaboration focuses on developing educational materials about equine botulism prevention and treatment for Federation members.
As a key highlight, Neogen manufactures BotVax® B, the only USDA-approved vaccine for Type B botulism in horses. The partnership aims to raise awareness about this deadly neurotoxin that can be found in hay, feed, and soil, threatening equine health.
The renewal demonstrates Neogen's continued commitment to equine health and safety, with both organizations expressing satisfaction with their first year of collaboration and optimism for future developments in equine wellness.
Neogen Corporation (NASDAQ: NEOG) has scheduled its first-quarter earnings release for October 9, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern time to discuss the financial results.
Investors can access the conference call via toll-free numbers for North America (1-800-549-8228) and International (+1 646-564-2877) using Conference ID 49915. A replay will be available through the company's Investor Relations website and via phone using passcode 49915.
Neogen Corporation (NASDAQ: NEOG) announced that Chief Financial Officer and Chief Operating Officer David Naemura plans to leave the company. Naemura will continue in his roles until after the company's 10-Q filing in October, with his departure no later than the end of 2025.
The company has initiated a search for a new CFO through a leading executive search firm. During the transition, Bill Waelke, Vice President of Investor Relations & Treasury, will support investor inquiries, while Jim Walter, Vice President of Global Operations, will assume oversight of Global Procurement, reporting to CEO Mike Nassif.
Neogen Corporation (NASDAQ: NEOG) announced significant changes to its Board of Directors. William Boehm, who has served since 2011 and currently chairs the Audit Committee, will retire effective October 23, 2025.
The company appointed Avi Pelossof to the Board effective October 24, 2025. Pelossof brings over 25 years of diagnostics market experience, most recently serving as CEO of Immucor Inc., where he led the company's turnaround and acquisition by Werfen in 2023. Previously, as Global President of Infectious Disease at Alere Inc., he built a $750 million global portfolio and launched the first FDA CLIA-waived point-of-care molecular test.
Neogen Corporation (NASDAQ: NEOG) has announced a strategic partnership with Biomatter to develop new enzyme-based products for food safety applications. The collaboration combines Neogen's expertise in food testing and risk mitigation with Biomatter's proprietary Intelligent Architecture™ platform, which uses AI and physical modeling for enzyme design.
The partnership aims to create innovative enzyme-based solutions that will enhance detection capabilities and improve efficiency in food safety testing. This initiative represents a significant step forward in advancing food security and protecting the global food supply chain.
Neogen Corporation (NASDAQ: NEOG) reported challenging fourth-quarter 2025 results, with revenue declining 4.8% to $225.5 million. The company recorded a significant net loss of $612.2 million, primarily due to non-cash goodwill impairment related to the 3M Food Safety Division acquisition. Adjusted Net Income was $11.3 million ($0.05 per share), while Adjusted EBITDA reached $40.6 million.
The Food Safety segment revenue decreased 3.0% to $161.8 million, while Animal Safety segment revenue fell 8.9% to $63.6 million. Gross margin declined to 41.2% from 47.9% year-over-year. For fiscal 2026, Neogen projects revenue between $820-840 million and Adjusted EBITDA of $165-175 million.
Neogen Corporation (NASDAQ: NEOG) has launched Molecular Detection Assay - Listeria Right Now™, a rapid testing solution for detecting Listeria species in environmental samples. The innovative test delivers results in approximately two hours, significantly faster than traditional methods that require 24-48 hours.
The new solution features a streamlined testing process with no enrichment required, user-friendly sampling devices for various surface types, and color-coded reagent pellets for improved workflow efficiency. The system can test up to 96 samples per run and supports simultaneous testing across multiple qualitative assays.
Neogen is showcasing the product at IAFP 2025 in Cleveland, Ohio, where food safety professionals can experience live demonstrations at Booth #511.
Neogen Corporation (NASDAQ: NEOG), a global leader in food safety solutions, has appointed Mike Nassif as its new CEO and President, effective August 11, 2025. Nassif, who will also join Neogen's Board of Directors, succeeds John Adent after his eight-year tenure.
Nassif joins from Siemens Healthineers, where he served as Global President of Point-of-Care Diagnostics, demonstrating success in driving business growth. His appointment aligns with Neogen's focus on achieving growth, profitability, and operational targets through its portfolio of food and animal safety solutions.